WW International, Inc. · NASDAQ:WW
WW International — Q3 2026 Earnings Presentation
27 slides from WW International's earnings presentation, Nov 5, 2026
Slide 1: Q3 2026 Shareholder Letter
MADE FOR #1 most trusted Weight Loss Program in 2026 according to Newsweek / BrandSpark NAME: kimberley progress: -32 lbs program: points * MEMBERS Q3 2026 Shareholder Letter nov 5 2026
Slide 2: Business Update
Business Update Q3 2026 reflects growth in our higher-value offerings Revenue: Q3 Revenue was $152.9 million, down 11% year-over-year, while Clinical Subscription Revenue grew 48% year-over-year to $38.0 million. Core+: Q3 Core+ End of Period Subscribers reached 546 thousand, up 16% year-over-year,
Slide 3: One Strategy, One Platform
ONE STRATEGY ONE PLATFORM ADA PTING TO THE MARKET SUPPORT AT EVERY STAGE $1.15B Total debt, before vs. at emergence Q2 2025 RESET Reset the balance sheet and set four of debt removed from the balance sheet $1.6B $465M strategic pillars. Before At emergence $18.52 Reven u e per su bscriber by quarter
Slide 4: To Our Valued Shareholders
To Our Valued Shareholders Weight Watchers was built on a conviction that has only grown more relevant: reaching and sustaining weight loss requires the right combination of treatment, guidance, and support. For more than six decades, our science-backed programs, coaches, and community have helped m
Slide 5: What our Offerings Share
What our Offerings Share Core, our digital Behavioral offering, provides science-backed weight-management tools and behavioral guidance. Core+, our higher-value Behavioral offering, adds coaching, workshops, virtual experiences, and specialized programs, including GLP-1 Success, which supports membe
Slide 6: Three Levels of Support
Three Levels of Support MED+ | GLP-1 Access Get access to FDA-approved GLP-1 medication, if eligible, and clinical support.4 CORE+ | Signature Lose weight with our signature program — featuring human coaches and expert support. CORE | Basic Get simple and effective tools to lose weight and build hea
Slide 7: Q3 2026 Financial Performance and 2026 Outlook
Q3 2026 Financial Performance and 2026 Outlook 6
Slide 8: Subscribers and ARPU
Subscribers and ARPU Core+ Subscribers grew for a fourth consecutive quarter Monthly Subscription Revenue Per Behavioral and Clinical ARPUi Average Subscriber (ARPU)i Clinical Behavioral $21.17 $79.23 $20.90 $70.82 $20.59 $68.52 $67.55 $68.25 $18.73 $17.04 $17.21 $18.52 $16.82 +14% Y/Y $16.39 $16.32
Slide 9: Revenue and Gross Margin
Revenue and Gross Margin Clinical Subscription Revenue up 48% year-over-year Q3 Revenue was $152.9 million. Clinical Subscription Revenue grew 48% year-over-year to $38.0 million and represented 25% of total Revenue, up from 15% in Q3 2025. Within Behavioral Subscription Revenue, declines continue t
Slide 10: Operating Expenses
Operating Expenses Lowest marketing quarter of the year, as planned Q3 Marketing expenses were $33.1 million, or 21.6% of Revenue. Following elevated peak-season investment in Q1, particularly in Clinical, we continued to recalibrate marketing spend across our portfolio of offerings. Q3 SG&A expense
Slide 11: Profitability
Profitability Positive Q3 Net Income of $15.1 million and Adjusted EBITDAi of $51.7 million reflect strong profitability Q3 2026 Net Income was $15.1 million (9.9% Net Income Margin), which included $13.0 million of depreciation and amortization, $10.9 million of interest expense and $10.7 million o
Slide 12: Cash Flow and Balance Sheet
Cash Flow and Balance Sheet Cash balance up $25 million from Q2 2026 Cash and Cash Equivalents were $126.4 million at the end of Q3 2026. Cash Flow from Operations was $32.3 million in the quarter, which includes $11.4 million of quarterly interest to service our term loan. The cash balance at the e
Slide 13: 2026 Outlook
2026 Outlook We are narrowing our previously provided 2026 guidance ranges. We now expect Revenue of $625 million – $630 million (previously $620 million – $635 million) and Adjusted EBITDAi of $110 million – $115 million (previously $105 million – $115 million). Revenue Within Behavioral, we contin
Slide 14: Third Quarter Conference Call and Webcast; About Weight Watchers
Third Quarter Conference Call and Webcast The Company has scheduled a conference call today at 8:30 a.m. ET to discuss results. The webcast of the conference call will be available on the Company’s corporate website, corporate.ww.com, under Events and Presentations. A replay of the webcast will be a
Slide 15: Sources, Definitions and Financial Details
Sources, Definitions and Financial Details 14
Slide 16: Sources
Sources * At 6 months, participants in a clinical trial of the WW program lost an average of 12 lbs (5.4% of body weight). Palacios et al. Effectiveness of a digital weight management program on diet quality: A randomized controlled trial. AJCN. 2025. ** At 12 months, members lost on average 44.5 lb
Slide 17: Fresh Start Accounting and Predecessor and Successor Periods
Fresh Start Accounting and Predecessor and Successor Periods In connection with the Company’s emergence from its financial reorganization process on June 24, 2025, the Company’s nine months ended September 30, 2025 includes a “Predecessor” period from December 29, 2024 to June 24, 2025, and a “Succe
Slide 18: Definitions and Performance Indicators
Definitions and Performance Indicators “Behavioral” business refers to providing subscriptions to the Company’s digital product offerings with the option to upgrade to unlimited access to the Company’s workshops and certain tailored versions of its behavior change program. “Clinical” business refers
Slide 19: Cautionary Note on Forward Looking Statements
Cautionary Note on Forward Looking Statements This shareholder letter includes “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, in particular, any statements about
Slide 20: Reconciliation to GAAP Measures of Non-GAAP Financial Measures
Reconciliation to GAAP Measures of Non-GAAP Financial Measures To supplement the Company’s consolidated results presented in accordance with accounting principles generally accepted in the United States (“GAAP”), the Company has disclosed non-GAAP financial measures of operating results that exclude
Slide 21: Operational Statistics
Operational Statistics (In Thousands, Except Percentages and Monthly Subscription Revenue Per Average Subscriber) Unaudited Successor Three Months Ended Three Months Ended September 30, 2026 September 30, 2025 Variance Variance (Constant Currency) (Constant Currency) Incoming Subscribers(1) Incoming
Slide 22: Net Income (Loss) to Adjusted EBITDA
Net Income (Loss) to Adjusted EBITDA (In Thousands, Except Percentages); Unaudited Successor Q3 2026 Q2 2026 Q1 2026 Q4 2025 Q3 2025 Net Income (Loss) $ 15,108 $ 14,074 $ (52,000) $ (5,833) $ (57,516) Net Income (Loss) Margin 9.9% 8.7% (30.9%) (3.6%) (33.4%) Interest 10,861 11,588 11,475 11,767 12,0
Slide 23: Gross Profit, Marketing, Product Development, SG&A Expenses
Gross Profit, Marketing Expenses, Product Development Expenses, Selling, General & Administrative (SG&A) (In Thousands, Except Percentages); Unaudited Successor Q3 2026 Q3 2025 Product Selling, General Product Selling, General Gross Marketing Development and Administrative Gross Marketing Developmen
Slide 24: Consolidated Balance Sheets
Consolidated Balance Sheets (In Thousands); Unaudited Successor September 30, 2026 December 31, 2025 ASSETS CURRENT ASSETS Cash and cash equivalents $ 126,442 $ 160,279 Restricted cash 5,796 6,298 Receivables (net of allowances: September 30, 2026 - $2,132 and December 31, 2025 - $1,651) 11,977 16,3
Slide 25: Consolidated Statements of Operations
Consolidated Statements of Operations (In Thousands, Except Per Share Amounts); Unaudited Successor Three Months Ended Three Months Ended September 30, 2026 September 30, 2025 Subscription revenue, net(1) $ 151,960 $ 170,929 Other revenue, net(2) 941 1,162 Revenue, net 152,901 172,091 Cost of subscr
Slide 26: Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows (In Thousands); Unaudited Successor Predecessor Nine Months Ended Period from Period from September 30, 2026 June 25, 2025 through December 29, 2024 through September 30, 2025 June 24, 2025 Operating activities: Net (loss) income $ (22,818) $ (56,262) $ 1,118,10
Slide 27: Contact Information
Contact Information Investors Media Anna Kate Heller Melissa Garbayo WeightWatchers@icrinc.com melissa.garbayo@ww.com 26